Inhibition of Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocyte (CTL) activity by soluble HLA class I in vitro.
In the present study, the effects of soluble HLA (sHLA) class I molecules against EBV-specific CTL were examined. Two different sources of sHLA class I, either bioengineered spliced form of HLA-B7 (sB7) or natural production from EBV-transformed B cells (natural sHLA), were added during the induction of CTL or incubated with MHC-restricted CD8+ CTL, which were selected by immunobeads just before testing for their cytotoxic activity. Both sB7 and natural sHLA class I blocked the generation of CD8+ CTL and also inhibited the cytotoxic activity of established CTL in a dose-dependent manner. In both ways, natural sHLA class I was effective in 10-fold lower concentrations compared with sB7. The inhibitory effect did not require a sharing of the HLA allotypes between sHLA and the CTL. CTL, after being treated with sHLA, underwent apoptosis, which was considered here as the main mechanism.
Gansuvd
B
B
Department of Haematology, Institute of Clinical Pathology, Ulaanbaatar, Mongolia, Japan.
Hagihara
M
M
Munkhbat
B
B
Kanai
N
N
Morita
N
N
Munkhtuvshin
N
N
Chargui
J
J
Kato
S
S
Hotta
T
T
Tsuji
K
K
D017209:Apoptosis; D001402:B-Lymphocytes / Q000821:virology; D002460:Cell Line; D002472:Cell Transformation, Viral; D006680:HLA Antigens / Q000494:pharmacology*; D015793:HLA-B7 Antigen / Q000494:pharmacology; D004854:Herpesvirus 4, Human / Q000276:immunology*; D015395:Histocompatibility Antigens Class I / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D011994:Recombinant Proteins / Q000494:pharmacology; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology / Q000276:immunology*
D006680:HLA Antigens; D015793:HLA-B7 Antigen; D015395:Histocompatibility Antigens Class I; D011994:Recombinant Proteins